A patient shall be eligible for treatment with an investigational drug, biological product, or device if the patient has:
- (1) A terminal illness that is attested to by the patient's treating health care provider;
- (2) Considered all other treatment options currently approved by the United States Food and Drug Administration;
- (3) Received a recommendation from the patient's treating health care provider for an investigational drug, biological product, or device;
- (4) Given written informed consent for the use of the investigational drug, biological product, or device; and
- (5) Documentation from the treating health care provider that the patient meets the requirements of this section.
Effective: June 29, 2017
History: Created 2017 Ky. Acts ch. 65, sec. 3, effective June 29, 2017. Formerly codified as KRS 217.5405.